EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Management of Spinal Surgery in Severe Hemophilia B under Marstacimab Prophylaxis

Christian Pfrepper, Maria Weise, Ulrich Kalus, Annelie Siegemund, Thomas Siegemund, Tristan Klöter

Hämostaseologie · 2026-11-13

DOI: 10.1055/a-2987-1774 ↗
AbstractBibliografische Angaben

Abstract

AbstractMarstacimab is an antibody directed against tissue factor pathway inhibitor aiming to rebalance hemostasis in patients with severe hemophilia. There are currently no reports on the management of patients under marstacimab prophylaxis undergoing major surgeries outside clinical trials. We report a patient with severe hemophilia B and a history of myocardial infarction who underwent major elective spinal surgery followed by urgent revision surgery while receiving marstacimab prophylaxis. For the first operation, the last dose of marstacimab was administered 12 days before surgery and plasma-derived factor (F) IX was administered to achieve a trough level of 50 IU/dL to maintain hemostasis. For the second operation, performed only seven days after the last marstacimab dose, the trough level was reduced to 30 IU/dL to limit the potential additive prothrombotic effect of both agents, as relevant residual marstacimab concentrations were expected. No relevant bleeding occurred. To prevent thrombotic complications, both surgeries were performed under thromboprophylaxis with low molecular weight heparin, and acetylsalicylic acid was continued. Thrombin generation was normalized under marstacimab and equal or higher than with 54 IU/dL FIX activity depending on the assay. This supports our strategy of providing sufficient FIX replacement while minimizing thrombotic risk. Due to the long half-life of marstacimab, low factor trough levels may be sufficient to provide adequate hemostasis in patients undergoing major surgeries.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →